Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3021-3040 of 3,900 trials

Eculizumab for Hypertensive Emergency-Associated Kidney Condition

We are studying whether Eculizumab can improve kidney function in patients with a severe kidney condition linked to high blood pressure. This trial will help us understand its effects on dialysis needs and overall health.

Atypical Hemolytic Uremic Syndrome (aHUS)1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Immune Thrombocytopenia: Dexamethasone vs. IVIg

We are studying whether oral dexamethasone is as effective as intravenous immunoglobulin combined with prednisone for adults with immune thrombocytopenia experiencing bleeding. This research may help identify a more convenient treatment option.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Lyell Syndrome: Mesenchymal Stromal Cells Treatment

We are testing a new treatment using mesenchymal stromal cells for patients with Lyell syndrome. The study aims to see if this treatment can help improve skin healing and overall health.

Lyell Syndrome>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyHematology

Sepsis Treatment: Hydrocortisone and Fludrocortisone Study

We are investigating whether a combination of hydrocortisone and fludrocortisone can improve outcomes for adults with sepsis in the ICU. This study aims to see if it helps reduce death or ongoing organ issues compared to a placebo.

Sepsis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Bariatric Surgery: Metformin for Diabetes Management

We are studying whether adding metformin to standard care helps people who had bariatric surgery stay diabetes-free longer. This trial focuses on former type 2 diabetes patients and their overall health and quality of life.

Type 2 Diabetes>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Glycerol Phenylbutyrate for Pyruvate Dehydrogenase Deficiency

We are studying whether Glycerol Phenylbutyrate can help reduce fatigue and improve quality of life for patients with Pyruvate Dehydrogenase Deficiency. The trial will also assess its safety and effects on neurodevelopmental symptoms.

Pyruvate Dehydrogenase Deficiency1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGastroenterologyNeurology

Seizures in Developmental and Epileptic Encephalopathies: LP352 Study

We are investigating whether LP352 can help reduce seizures in children and adults with developmental and epileptic encephalopathies. This study compares the medication to a placebo to assess its effectiveness and safety.

Developmental and Epileptic EncephalopathiesConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Multiple Myeloma: Elranatamab and Lenalidomide Study

We are testing a new combination treatment for newly diagnosed multiple myeloma to see if it works better than standard therapies. The study aims to evaluate its effectiveness and safety during different treatment phases.

Multiple Myeloma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Neonatal Hypoxic Ischemic Encephalopathy: Cord Blood Stem Cell Treatment

We are studying the safety and feasibility of using a baby's own cord blood stem cells to treat neonatal hypoxic ischemic encephalopathy. The trial also looks at how this treatment may help prevent long-term neurological problems.

Neonatal Hypoxic-Ischaemic Encephalopathy>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPediatrics

Sedation Study: Remimazolam vs. Midazolam for GI Endoscopy

We are comparing two sedation medications to see which one helps patients recover faster after upper GI endoscopy. We’ll also look at patient satisfaction and any side effects.

Healthy ParticipantsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Kidney Cancer: New Combination Therapies

We are studying new treatment combinations for people with recurrent kidney cancer after anti-PD-(L)1 therapy. The goal is to evaluate their safety and effectiveness in improving patient responses.

Clear Cell Renal Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Luspatercept for Anemia in Lower-Risk MDS Patients

We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.

Myelodysplastic Syndromes (MDS)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematology

Advanced Solid Tumors: LY3962673 Treatment

We are studying a new treatment called LY3962673 for people with advanced solid tumors. The goal is to understand its safety and how well it works compared to existing options.

KRAS G12D-mutant Solid Tumors>2 yearsSafety phase (I)Oncology

Liver Cancer: Tislelizumab Immunotherapy Study

We are testing a new immunotherapy for patients with liver cancer and moderate liver function. The study aims to see if it can improve treatment outcomes and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyOncology

Beta-Lactam Antibiotics: Precision Dosing in Critically Ill Children

We are studying a new dosing method for beta-lactam antibiotics in critically ill children to see if it helps them reach treatment goals faster than standard dosing. This may also help reduce their time in the hospital.

Systemic Infections>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

Urothelial Cancer: DDR Gene Testing for Chemotherapy Response

We are studying whether changes in DDR genes can help predict how well patients with advanced urothelial cancer respond to platinum-based chemotherapy. This may lead to better treatment decisions for patients based on their genetic profile.

Metastatic or Locally Advanced Urothelial Cancer1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Obstructive Colon Cancer: Neoadjuvant Chemotherapy Study

We are studying whether two chemotherapy regimens can improve treatment outcomes for patients with obstructive colon cancer after colostomy. The goal is to see if starting chemotherapy before surgery leads to better recovery and survival rates.

Colon Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Chronic Hypertension in Pregnancy: Aspirin Study

We are investigating whether low-dose aspirin can help prevent serious complications in pregnant women with chronic hypertension. This includes risks like preeclampsia and preterm delivery.

Pregnancy-Related Hypertension and Pre-Eclampsia6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Inflammatory Disorders: New Imaging Tracer 18F-AlF-FAPI-74

We are studying a new imaging tracer to see if it can better diagnose inflammatory disorders compared to the standard tracer. This trial includes patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis.

Fever of Unknown OriginIgG4-Related DiseaseAxial Spondyloarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyRheumatology

Multifocal Motor Neuropathy: Empasiprubart vs. IVIg

We are studying whether Empasiprubart can improve muscle strength and function in adults with Multifocal Motor Neuropathy compared to standard IVIg treatment.

Multifocal Motor Neuropathy>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology